Abstract: Disclosed are methods of treating autoimmune diseases by administering engineered T cells expressing a chimeric antigen receptor (CAR) that specifically binds C-type lectin-like molecule-1 (CLL-1). The CAR-T cells deplete CLL-1-expressing monocyte-derived macrophages that replace yolk sac-derived or other embryonically derived tissue-resident macrophages, thereby reducing inflammation and disease progression. The methods are applicable to multiple sclerosis and other autoimmune disorders.

Abstract: A portable lighting apparatus includes a handle, a light head pivotally coupled to the handle through a plurality of positions via a joint, a battery receptacle supported by the handle, a first light source supported in the light head, a second light source supported in the light head, and a user interface supported by the handle and configured to be selectively actuated by a user to operate the first light source and the second light source. The battery receptacle is configured to receive a rechargeable battery. The first light source includes a laser selectively operable to emit a single light wavelength, and the second light source includes one or more LEDs selectively operable to emit a distribution of light wavelengths.

Abstract: A portable lighting apparatus includes a handle, a light head pivotally coupled to the handle through a plurality of positions via a joint, a battery receptacle supported by the handle, a first light source supported in the light head, a second light source supported in the light head, and a user interface supported by the handle and configured to be selectively actuated by a user to operate the first light source and the second light source. The battery receptacle is configured to receive a rechargeable battery. The first light source includes a laser selectively operable to emit a single light wavelength, and the second light source includes one or more LEDs selectively operable to emit a distribution of light wavelengths.